Released Nov 5, 2020, after the close
10-Q filed Nov 5, 2020, 36 days after period end · 0001564590-20-051470
Q3 2020 · 10-Q
Revenue$34.61M$34.61M +718.0% vs Q3 2019−12.1% vs Q2 2020
Net Income-$3.35M-$3.35M N/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$0.09-$0.09 N/M vs Q3 2019N/M vs Q2 2020
Operating Income-$4,019,000N/M
Operating Cash Flowderived$10,646,000N/M
Free Cash Flowderived$10,646,000N/M
Margins · derived
Operating margin-11.6%+602.7 pt vs Q3 2019
Net margin-9.7%+581.1 pt vs Q3 2019
What the release said
The release
Same quarter
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Revenue | $34.61M | $4.23M | $4.29M | $2.66M |
| Net Income | -$3.35M | -$25.00M | -$21.54M | -$12.27M |
| EPS Diluted | -$0.09 | -$0.96 | -$0.87 | -$710.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR